Key result
Cancer patients receiving cardiotoxic anti-cancer therapies who contract COVID-19 face an increased risk of severe cardiotoxicity due to overlapping cardiovascular side effects from the infection and its treatments.
Why the study?
COVID-19 and its treatments may increase the risk of cardiotoxicity in cancer patients receiving potentially cardiotoxic agents, creating a need for evidence-based risk assessment and management strategies.
COVID-19 and its treatments may exacerbate cardiotoxicity in cancer patients receiving cardiotoxic therapies, highlighting the need for specialized cardio-oncology management.
Alerts clinicians to cardiotoxicity risks in cancer patients with COVID-19; leaves open optimal strategies pending prospective validation.
Cardiotoxicity induced by anti-cancer treatment has become a significant threat as the number of cardiotoxic anti-cancer agents is growing. Cancer patients are at an increased risk of contracting coronavirus disease 2019 (COVID-19) because of immune suppression caused by anti-cancer drugs and/or supportive treatment. Deterioration in lung functions due to COVID-19 is responsible for many cardiac events. The presence of COVID-19 and some of its treatment modalities may increase the chance of cardiotoxicity development in cancer patients receiving potentially cardiotoxic agents. This review provides evidence-based information on the cardiotoxicity risk in cancer patients clinically diagnosed with COVID-19 who are receiving potentially cardiotoxic anti-cancer agents. Proposed strategies relating to the management of this patient cohorts are also discussed.
No takes yet. Share an insight, caveat, or question.
Kobat et al. (2021) conducted a review in COVID-19 in cancer patients receiving cardiotoxic anti-cancer therapy. Cardiotoxic anti-cancer therapy and COVID-19 pharmacotherapies was evaluated. Cancer patients receiving cardiotoxic anti-cancer therapies who contract COVID-19 face an increased risk of severe cardiotoxicity due to overlapping cardiovascular side effects from the infection and its treatments.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: